Longer Duration of Treatment with ICIs Associated with a Higher Rate of Complete Response Among Patients with MMRd Cancers By Ogkologos - March 5, 2025 650 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a systematic review of published studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer EMA Recommends Extension of Indications for Selpercatinib MOST POPULAR Higher Rates of Metastasis-Free Survival in Men with High-Risk Non-Metastatic Prostate... January 11, 2022 Man Gets His First Haircut In 15 Years To Join The... August 21, 2019 PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous... December 17, 2025 Zanidatamab Demonstrates Meaningful Clinical Benefit with a Manageable Safety Profile in... June 7, 2023 Load more HOT NEWS FDA Approves Pembrolizumab Combination for the First-Line Treatment of Cervical Cancer Breast Cancer Patient Devotes Her Time to Driving Others to Treatment Finally Pregnant After Struggling With Infertility For Years, She Was Diagnosed... CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated...
